$6.85
6.58% today
Nasdaq, Apr 04, 09:47 pm CET
ISIN
US09058V1035
Symbol
BCRX
Sector
Industry

BioCryst Pharmaceuticals, Inc. Stock price

$6.83
-1.48 17.81% 1M
-0.75 9.89% 6M
-0.69 9.18% YTD
+2.23 48.48% 1Y
-9.93 59.25% 3Y
+4.78 233.17% 5Y
-2.86 29.52% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.50 6.82%
ISIN
US09058V1035
Symbol
BCRX
Sector
Industry

Key metrics

Market capitalization $1.53b
Enterprise Value $2.05b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.55
P/S ratio (TTM) P/S ratio 3.40
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 36.00%
Revenue (TTM) Revenue $450.71m
EBIT (operating result TTM) EBIT $-2.54m
Free Cash Flow (TTM) Free Cash Flow $-53.14m
Cash position $321.06m
EPS (TTM) EPS $-0.43
P/E forward negative
P/S forward 2.72
EV/Sales forward 3.64
Short interest 9.54%
Show more

Is BioCryst Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

BioCryst Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:

Buy
90%
Hold
10%

Financial data from BioCryst Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
451 451
36% 36%
100%
- Direct Costs 14 14
117% 117%
3%
437 437
34% 34%
97%
- Selling and Administrative Expenses 265 265
25% 25%
59%
- Research and Development Expense 173 173
19% 19%
38%
-1.30 -1.30
99% 99%
0%
- Depreciation and Amortization 1.25 1.25
25% 25%
0%
EBIT (Operating Income) EBIT -2.54 -2.54
98% 98%
-1%
Net Profit -89 -89
61% 61%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about BioCryst Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioCryst Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about 11 hours ago
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of April 1, 2025, as inducements material to each em...
Neutral
GlobeNewsWire
2 days ago
RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET.
Neutral
GlobeNewsWire
29 days ago
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as of March 3, 2025, as inducements material to each...
More BioCryst Pharmaceuticals, Inc. News

Company Profile

BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.

Head office United States
CEO Jon Stonehouse
Employees 580
Founded 1986
Website www.biocryst.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today